The NGS Conference 2018 brought together scientists, clinicians, and industry innovators to explore the latest advances in next-generation sequencing. This event highlighted practical applications, regulatory discussions, and translational strategies shaping genomic medicine.
As sequencing throughput and data complexity grew, the conference emphasized rigorous quality control, standardized pipelines, and reproducible workflows for research and diagnostics.
| Conference Track | Key Focus | Target Audience | Outcome |
|---|---|---|---|
| Clinical Genomics | Diagnostic pipelines, ACMG guidelines | Clinical lab directors, geneticists | Implementation frameworks for NGS testing |
| Data Analysis | Variant calling, interpretation tools | Bioinformaticians, researchers | Best practices for reproducible pipelines |
| Panels & Workshops | Hands-on training, QA/QC metrics | Lab managers, bioinformaticians | Skills for validating and scaling NGS workflows |
| Regulatory & Reimbursement | FDA perspectives, coverage policies | Regulatory affairs, payers | Insights on aligning assays with evolving policies |
Clinical Implementation of NGS
Sessions explored integrating NGS into routine diagnostics, addressing pre-analytical, analytical, and reporting challenges. Discussions highlighted structured reporting formats and continuous staff training.
Case studies from accredited labs demonstrated strategies to reduce turnaround time, minimize indeterminate results, and maintain compliance in a regulated environment.
Data Analysis & Interpretation
Speakers covered algorithm selection, fusion detection, and handling of tumor-normal pairs. Emphasis was placed on transparent documentation and cross-laboratory benchmarking to improve sensitivity and specificity.
The conference underscored the role of curated databases and standardized pipelines to support consistent variant classification across institutions.
Quality Control & Validation
Workshops detailed metrics such as coverage depth, uniformity, and limit of detection for various assay types. Participants reviewed checklists for method validation, including in silico, in vitro, and in silico comparisons.
Emphasis on version control, tracking reagent lot numbers, and maintaining auditable records helped labs strengthen CAP and ISO compliance.
Regulatory & Policy Landscape
Sessions highlighted evolving FDA guidance, laboratory-developed test oversight, and payer evidence requirements. Expert panels discussed alignment of clinical claims with assay performance metrics.
Attendees gained clarity on documentation needed for test submission, risk management, and post-market surveillance in a rapidly changing policy environment.
Future Directions for NGS in Precision Medicine
The trajectory from NGS Conference 2018 points toward broader multi-omics integration, real-time data interpretation, and more efficient reimbursement pathways.
Collaboration among clinicians, laboratorians, and policymakers will remain essential to align innovation with patient safety, equitable access, and meaningful clinical impact.
- Define a focused target panel before scaling to broader genomic testing
- Implement standardized bioinformatics pipelines with transparent QC thresholds
- Develop staff training programs to keep skills current with evolving guidelines
- Track regulatory updates and payer policies to support timely test adoption
- Use benchmarking projects to compare performance against recognized external schemes
FAQ
Reader questions
How can my lab transition from Sanger to NGS cost-effectively?
Start with a phased approach by validating NGS for a focused gene panel, leverage automation to reduce hands-on time, and consolidate bioinformatics workflows to reuse existing IT infrastructure where possible.
What are the main challenges in reporting NGS results for hereditary cancer panels?
Key challenges include classifying variants of uncertain significance, maintaining consistent allele frequency thresholds, ensuring proper consent processes, and keeping reporting aligned with dynamic evidence sources and guideline updates.
Which quality metrics should be monitored in an NGS clinical pipeline?
Monitor on-target and off-target coverage uniformity, duplicate alignment rate, indel and variant calling sensitivity, batch effects, and reagent performance to ensure robust and reproducible results across runs.
How do regulatory changes impact NGS test validation and deployment?
Regulatory updates may require additional analytical validation, new documentation for intended use, and clearer evidence of clinical utility; proactive engagement with accrediting bodies and payers supports smoother implementation and market access.